What is claimed is:

1. Use of paliperidone palmitate in the manufacture of a medicament for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder in a patient in need thereof who has been administered a first dose of a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M), wherein the use comprises a second dose of the paliperidone palmitate extended-release injectable suspension to be administered to a deltoid or gluteal muscle of the patient up to two weeks before or three weeks after a time that is six months after administration of the first dose, wherein there is no intervening dose of paliperidone palmitate between the first dose and the second dose,

wherein the paliperidone palmitate extended-release injectable suspension comprises about 312 mg/mL of paliperidone palmitate,

wherein the paliperidone palmitate extended-release injectable suspension is an aqueous composition which further comprises a suspending agent, a buffer, and optionally one or more of a preservative and an isotonizing agent,

wherein the first dose comprises about 1092 mg of paliperidone palmitate or about 1560 mg of paliperidone palmitate, and

wherein the second dose comprises about 1092 mg of paliperidone palmitate or about 1560 mg of paliperidone palmitate.

2. The use of claim 1, wherein the second dose is to be administered to the gluteal muscle.

3. The use of claim 1 or claim 2, wherein the patient has a steady state paliperidone plasma concentration at the time of the first dose.

4. The use of any one of the preceding claims, wherein the patient is in need of treatment for schizophrenia.

5. The use of any one of the preceding claims, wherein the first dose and the second dose each comprise about 1092 mg paliperidone palmitate.

6. The use of any one of claims 1-5, wherein the first dose and the second dose each comprise about 1560 mg paliperidone palmitate.

7. The use of any one of the preceding claims, wherein the plasma concentration of paliperidone in the patient is 5 to 50 ng/mL at the time of the second dose.

8. The use of claim 7, wherein when the first dose comprises 1092 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient is 5 to 30 ng/mL at the time of the second dose.

9. The use of claim 7, wherein when the first dose comprises 1560 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient is 9 to 40 ng/mL at the time of the second dose.

10. The use of any one of the preceding claims, wherein the plasma concentration of paliperidone achieves a peak of 10 to 150 ng/mL after administration of the second dose.

11. The use of claim 10, wherein when the first dose is 1092 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient achieves a peak of 10 to 125 ng/mL after administration of the second dose.

12. The use of claim 10, wherein when the first dose is 1560 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient achieves a peak of 35 to 145 ng/mL after administration of the second dose.

13. The use of any one of the preceding claims, wherein the paliperidone palmitate extended-release injectable suspension comprises:

about 312 mg/mL of the paliperidone palmitate;

8 mg/mL to 12 mg/mL of a wetting agent;

one or more buffering agents;

65 mg/mL to 85 mg/mL of the suspending agent; and
water q.s. ad 100%.

14. The use of claim 13, wherein the suspension is from pH 6.0 to pH 8.0.

15. The use of claim 13 or claim 14, wherein the one or more buffering agents comprise citric acid monohydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, or sodium hydroxide.

16. The use of claim 13, wherein the paliperidone palmitate extended-release injectable suspension comprises:

about 312 mg/mL of paliperidone palmitate;
about 10 mg/mL of polysorbate 20; and
about 75 mg/mL of polyethylene glycol 4000.

17. The use of any one of the preceding claims, wherein said patient in need thereof who has been administered a first dose of a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M) has also been administered a paliperidone palmitate extended-release injectable suspension having either a one-month dosing interval (PP1M) or a three-month dosing interval (PP3M) prior to administration of said first dose of PP6M.

18. The use of claim 17, wherein said patient in need thereof has been administered said PP1M for at least four months or said PP3M for at least one 3-month interval prior to administration of said first dose of PP6M.

19. The use of claim 17 or claim 18, wherein:

(a) the dose of said PP1M was about 156 mg or about 234 mg paliperidone palmitate; or

(b) the dose of said PP3M was about 546 mg or about 819 mg paliperidone palmitate.

20. The use of claim 18 or claim 19, wherein:

(a) said patient has been administered PP1M for at least four months, and said first dose of PP6M has been administered 1 month ± 7 days after the last dose of said PP1M has been administered; and/or

(b) (i) if the last dose of said PP1M was about 156 mg paliperidone palmitate, said first dose of PP6M was about 1092 mg paliperidone palmitate; or

(ii) if the last dose of said PP1M was about 234 mg paliperidone palmitate, said first dose of PP6M was about 1560 mg paliperidone palmitate.

21. The use of claim 18 or claim 19, wherein:

(a) said patient has been administered PP3M for at least one 3-month interval, and said first dose of PP6M has been administered 3 months ± 14 days after the last dose of said PP3M has been administered; and/or

(b) (i) if the last dose of said PP3M was about 546 mg paliperidone palmitate, said first dose of PP6M was about 1092 mg paliperidone palmitate; or

(ii) if the last dose of said PP3M was about 819 mg paliperidone palmitate, said first dose of PP6M was about 1560 mg paliperidone palmitate.

22. The use of any one of the preceding claims, wherein said PP6M is in a pre-filled syringe having a tip cap and a thin-walled 20 gauge 1.5 inch needle, and optionally wherein the syringe is shaken with the tip cap pointing up for at least 15 seconds, and after a rest, the syringe is shaken again for another 15 seconds before administration of said PP6M.

23. The use of any one of claims 17-20 or 22, wherein said PP1M comprises:

140 mg/mL to 180 mg/mL of paliperidone palmitate;

8 mg/mL to 16 mg/mL of a wetting agent;

5 mg/mL to 15 mg/mL of one or more buffering agents;

20 mg/mL to 40 mg/mL of a suspending agent; and

water q.s. ad 100%,

optionally wherein said PP1M comprises:

about 156 mg/mL of paliperidone palmitate;

about 12 mg/mL of polysorbate 20;

about 30 mg/mL of polyethylene glycol 4000;
about 5 mg/mL citric acid monohydrate;
about 2.5 mg/mL sodium dihydrogen phosphate monohydrate;
about 5 mg/mL disodium hydrogen phosphate anhydrous;
about 2.84 mg/mL sodium hydroxide; and
water for injection.

24. The use of any one of claims 17-19, 21 or 22, wherein said PP3M comprises:
280 mg/mL to 350 mg/mL of paliperidone palmitate;
8 mg/mL to 12 mg/mL of a wetting agent;
5 to 15 mg/mL of one or more buffering agents;
65 mg/mL to 85 mg/mL of a suspending agent; and
water q.s. ad 100%,
optionally wherein said PP3M comprises:
about 312 mg/mL of paliperidone palmitate;
about 10 mg/mL of polysorbate 20;
about 75 mg/mL of polyethylene glycol 4000;
about 7.5 mg/mL citric acid monohydrate;
about 6 mg/mL sodium dihydrogen phosphate monohydrate;
about 5.4 mg/mL sodium hydroxide; and
water for injection.

25. The use of any one of the preceding claims, wherein the treatment is associated with:
(a) the body weight of the patient being stabilized, wherein stabilized optionally refers to a body mass index (BMI) change of -1 to +1, preferably from -0.5 to +0.5, further preferably 0, from the time of the first dose of PP6M; or
(b) the body weight of the patient decreasing;
optionally wherein the body weight of the patient is stabilized or decreased within twelve months from the time of the first dose of PP6M.

26. The use of any one of the preceding claims, wherein the patient has a body mass index (BMI) of 25 to less than 30.

27. The use of any one of the preceding claims, wherein the patient has an age of 18 years old to 25 years old.

28. The use of any one of the preceding claims, wherein the PP6M is provided in a prefilled syringe prefilled with either 700 mg eq. (3.5 mL) paliperidone as 1092 mg paliperidone palmitate, or 1000 mg eq. (5.0 mL) paliperidone as 1560 mg paliperidone palmitate, and wherein the paliperidone palmitate is to be administered in a single injection.